Article
Oncology
Cheng Qian, Dan Li, Yu Chen
Summary: The ETS family of proteins plays critical roles in prostate cancer, and gene fusion and overexpression of certain members have been linked to the development of this cancer. This review provides an overview of the discovery, classification, and therapeutic targeting of ETS family members in prostate cancer.
Article
Medicine, Research & Experimental
Dell Liu, Michael A. Augello, Ivana Grbesa, Davide Prandi, Yang Liu, Jonathan E. Shoag, R. Jeffrey Karnes, Bruce J. Trock, Eric A. Klein, Robert B. Den, Francesca Demichelis, Elai Davicioni, Andrea Sboner, Christopher E. Barbieri
Summary: The study reveals that different subtypes of prostate cancer follow distinct pathways of progression, with late events associated with prognosis. Late events show strikingly different features at radical prostatectomy, suggesting that common clinical parameters may be influenced by underlying tumor lineage and impact treatment decisions.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Pathology
Yuri Tolkach, Romina Zarbl, Simone Bauer, Manuel Ritter, Joerg Ellinger, Stephan Hauser, Laura Hueser, Sabine M. Klauck, Peter Altevogt, Holger Sultmann, Dimo Dietrich, Glen Kristiansen
Summary: CD24 is overexpressed in many human cancers, including prostate cancer, and its up-regulation can be influenced by DNA methylation of the CD24 promoter. Higher levels of CD24 expression are associated with poorer outcomes in prostate cancer patients, including shorter biochemical recurrence-free survival. Overexpression of ERG and PTEN deficiency are also correlated with increased CD24 expression levels in prostate cancer.
AMERICAN JOURNAL OF PATHOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Ealia Khosh Kish, Muhammad Choudhry, Yaser Gamallat, Sabrina Marsha Buharideen, D. Dhananjaya, Tarek A. Bismar
Summary: The ERG gene is consistently overexpressed in prostate cancer and is mainly due to the fusion of ERG and TMPRSS2 genes. ERG enhances tumor growth by promoting inflammatory and angiogenic responses and is involved in the epithelial-mesenchymal transition, increasing the metastatic ability of prostate cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Urology & Nephrology
Camilo Arenas-Gallo, Jude Owiredu, Ilon Weinstein, Patrick Lewicki, Spyridon P. Basourakos, Randy Vince, Bashir Al Hussein Al Awamlh, Fredrick R. Schumacher, Daniel E. Spratt, Christopher E. Barbieri, Jonathan E. Shoag
Summary: This review discusses racial differences in genetic mutations related to prostate cancer and the role of genomics in understanding racial disparities in prostate cancer outcomes. Recent advances in genomics have provided insights into the genomic pathogenesis of prostate cancer and identified different molecular drivers of the disease, some of which show variations across racial backgrounds. However, the extent to which genomics can explain racial differences in prostate cancer outcomes remains unclear, highlighting the need for collaborative genomic studies that include diverse racial and ethnic populations.
NATURE REVIEWS UROLOGY
(2022)
Article
Oncology
Yingchun Liang, Enlin Rong, Jin Qian, Chenkai Ma, Jimeng Hu
Summary: In this study, the researchers analyzed the transcriptome of 231 patients with metastatic prostate cancer and identified four distinct biological subtypes. They found that the luminal subtype had higher androgen receptor expression and copy number alterations, while genes in the HRR pathway were downregulated in most subtypes except HRR and NE subtypes. The researchers also found that the basal subtype had a higher frequency of the TMPRSS2-ERG fusion.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Qiong Wang, Junxiu Chen, Sandeep Singh, Zhongqiu Xie, Fujun Qin, Xinrui Shi, Robert Cornelison, Hui Li, Hai Huang
Summary: This study examined the landscape of chimeric RNAs in different types of prostate cancer cell lines and identified chimeric RNAs specifically expressed in neuroendocrine prostate cancer (NEPC). Experimental validation and in silico analysis showed that these chimeric RNAs may serve as biomarkers for tumor malignancy and poor clinical prognosis.
CELL AND BIOSCIENCE
(2022)
Article
Oncology
Susanne G. Kidd, Mari Bogaard, Kristina T. Carm, Anne Cathrine Bakken, Aase M. V. Maltau, Marthe Lovf, Ragnhild A. Lothe, Karol Axcrona, Ulrika Axcrona, Rolf I. Skotheim
Summary: This study aimed to determine the prognostic value of candidate biomarkers transcriptional regulator ERG and related ETS family genes in prostate cancer, while considering tumor heterogeneity. The results showed that ERG protein has independent prognostic value in predicting biochemical and clinical recurrence of prostate cancer, and appears to have the greatest prognostic value for patients with Grade Groups 4-5.
MOLECULAR ONCOLOGY
(2022)
Article
Oncology
Andrei Daniel Timofte, Irina-Draga Caruntu, Adrian C. Covic, Monica Hancianu, Nona Girlescu, Mariana Bianca Chifu, Simona Eliza Giusca
Summary: Prostate cancer is a common malignancy with diverse clinical outcomes. This study investigated the relationship between renal function and different molecular subtypes of prostate adenocarcinomas. The study analyzed 72 patients with prostate cancer and associated chronic kidney disease who underwent radical prostatectomy. The results showed that the overexpression of SPINK1 was associated with higher kidney disease stages and serum creatinine levels, while TFF3 was linked to kidney function. The study also revealed associations between kidney disease stages and prognostic grade groups in different molecular subtypes, highlighting the complex interplay between kidney function and tumor behavior.
Article
Multidisciplinary Sciences
Eva Shrestha, Jonathan B. Coulter, William Guzman, Busra Ozbek, Megan M. Hess, Luke Mummert, Sarah E. Ernst, Janielle P. Maynard, Alan K. Meeker, Christopher M. Heaphy, Michael C. Haffner, Angelo M. De Marzo, Karen S. Sfanos
Summary: The study suggests that bacterial infections may initiate driver gene alterations in prostate cancer, with infection-induced ERG+ fusions being an early alteration in the carcinogenic process, potentially originating from proliferative inflammatory atrophy as a precursor.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Cell Biology
Shimiao Zhu, Zhao Yang, Zheng Zhang, Hongli Zhang, Songyang Li, Tao Wu, Xuanrong Chen, Jianing Guo, Aixiang Wang, Hao Tian, Jianpeng Yu, Changwen Zhang, Lei Su, Zhiqun Shang, Changyi Quan, Yuanjie Niu
Summary: Resistance to antiandrogen is lethal for castration-resistant prostate cancer (CRPC). In this study, we identified HOXB3 as an independent risk factor for progression and death in metastatic CRPC. We demonstrated that HOXB3 activation was associated with WNT pathway genes expression, and suppression of HOXB3 sensitized CRPC to abiraterone treatment. Our findings suggest that targeting HOXB3 may benefit a subgroup of CRPC resistant to antiandrogen therapy.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Masayuki Hagiwara, Yota Yasumizu, Nami Yamashita, Hasan Rajabi, Atsushi Fushimi, Mark D. Long, Wei Li, Atrayee Bhattacharya, Rehan Ahmad, Mototsugu Oya, Song Liu, Donald Kufe
Summary: MUC1-C associates with E2F1 and activates a novel pathway related to prostate cancer stem cell function.
Article
Biochemistry & Molecular Biology
Komal Raina, Rama Kant, Ram R. Prasad, Kushal Kandhari, Munendra Tomar, Neha Mishra, Robin Kumar, Jennifer T. Fox, Shizuko Sei, Robert H. Shoemaker, Yu Chen, Paul Maroni, Chapla Agarwal, Rajesh Agarwal
Summary: This study compared the pathological and molecular markers of TMPRSS2-ERG fusion and PTEN loss-driven versus non-fusion-driven prostate tumorigenesis in mice. The results showed that both mouse models exhibited growth and progression of prostate intraepithelial lesions to adenocarcinoma stages, although at different rates. The TMPRSS2-ERG. Pten(flox/flox) mice had slower initiation of tumorigenesis but faster progression through different stages, while the Hi-Myc(+/)(-) mice had rapid initiation but slower progression. Additionally, high-grade undifferentiated tumors were observed in the Hi-Myc(+/)(-) mice at advanced stages compared to the fusion-driven TMPRSS2-ERG. Pten(flox/flox) mice.
MOLECULAR CARCINOGENESIS
(2022)
Article
Oncology
Sini K. Eerola, Annika Kohvakka, Teuvo L. J. Tammela, Paivi J. Koskinen, Leena Latonen, Tapio Visakorpi
Summary: The study found that the oncogenic PIM family kinases are upregulated in prostate cancer, with even higher expression levels in castration-resistant prostate cancer. There is a significant association between upregulated PIM family members and the ERG and MYC oncoproteins, with ERG directly upregulating the expression of PIM genes. These findings suggest a cooperative role of PIM, ERG, and MYC in prostate cancer development and progression, with potential implications for targeted therapies.
Article
Oncology
Tanja Spethmann, Lukas Clemens Boeckelmann, Vera Labitzky, Ann-Kristin Ahlers, Jennifer Schroeder-Schwarz, Sarah Bonk, Ronald Simon, Guido Sauter, Hartwig Huland, Robert Kypta, Udo Schumacher, Tobias Lange
Summary: The junction plakoglobin (JUP) protein has both oncogenic and tumor suppressor functions in prostate cancer, with high expression associated with adverse tumor characteristics and poor prognosis in some patient subsets.
MOLECULAR ONCOLOGY
(2021)
